OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer

Trial Profile

OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms Opti-HER; OptiHerHEART
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2013 Planned end date changed from 1 May 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top